Describe the Adrenoreceptors by subunit, distribution, effects (including non-cardiovascular effects)
| Receptor | Subunit | Distribution | Effect | Non-cardiovascular effects |
|---|---|---|---|---|
| α₁ | Gq → ↑ IP₃/DAG → ↑ Ca²⁺ | Vascular smooth muscle, iris radial muscle, prostate/bladder neck, GI/GU sphincters | Smooth muscle contraction → vasoconstriction, mydriasis, urinary retention | • Mydriasis via radial muscle contraction • GI sphincter contraction • Bladder neck/prostate contraction • Piloerection • Skin vasoconstriction |
| α₂ | Gi → ↓ adenylate cyclase → ↓ cAMP | Presynaptic sympathetic nerve terminals, CNS, platelets, pancreatic β cells | ↓ noradrenaline release; ↓ sympathetic outflow; ↓ insulin; platelet aggregation | • Reduced insulin secretion>higher BGls • Reduced sympathetic outflow, sedation/analgesia • Reduced noradrenaline release |
| β₁ | Gs → ↑ adenylate cyclase → ↑ cAMP | Heart, juxtaglomerular cells of kidney | ↑ HR, ↑ contractility, ↑ conduction; ↑ renin | • Increased renin release |
| β₂ | Gs → ↑ adenylate cyclase → ↑ cAMP | Bronchial smooth muscle, skeletal-muscle vasculature, uterine smooth muscle, GI smooth muscle | Smooth muscle relaxation → bronchodilation, vasodilation, uterine relaxation | • Bronchodilation • Increased aqueous humour production[hence why beta blockers are used in glaucoma] • Reduced GI motility • Detrusor relaxation • Uterine relaxation • Tremor • Increased K uptake into cells>hypokalaemia • Increased glycogenesis>increased BGL • Increased lipolysis • Increased insulin secretion>lower BGLs |
| β₃ | Gs → ↑ cAMP | Adipose tissue, bladder detrusor | Lipolysis; detrusor relaxation | • Increased lipolysis |
What is the effect of Alpha agonism and how can it be useful?
α₁ receptor → Gq → ↑ IP₃/DAG → ↑ intracellular Ca²⁺ → smooth-muscle contraction
- Blood vessels: vasoconstriction, useful in shock (noradrenaline has stronger alpha effect than adrenaline and is often used for this reason as a vasopressor, adrenaline also useful in anaphylactic shock for this reason)
- Nasal mucosa: reduced mucosal oedema, useful in nasal decongestion
- Eye radial muscle: mydriasis, e.g. phenylephrine to look at retina
- Bladder neck/prostate: urinary retention, usually this is a negative effect
- GI/GU sphincter: contraction
- Skin: vasoconstriction, useful for achieving haemostasis
α₂ receptor → Gi → ↓ cAMP
- Presynaptic effect and CNS effect: reduces noradrenaline release, reduces sympathetic outflow, reduces BP/HR , causes sedation, analgesia, (clonidine and Dexmedetomidine useful for this)
Alpha and Beta agonists; their pharmacodynamics and pharmacokinetics
| Drug | Main receptors | Main PD effect | Typical clinical role | Key PK |
|---|---|---|---|---|
| Adrenaline | α₁,=β₁=β₂ >α₂ | ↑ HR/contractility[chronotropy/inotropy], vasoconstriction, bronchodilation | Anaphylaxis, cardiac arrest, severe shock | IV/IM/SC; rapid onset, short duration; metabolised by COMT + MAO |
| Noradrenaline | α₁>α₂>β₁ minimal β₂ | ↑ SVR/MAP, some ↑ contractility; reflex bradycardia possible | Vasodilatory shock/vasopressor [slightly more α₁ than adrenaline] | IV infusion; very short half-life; metabolised by COMT + MAO |
| Isoprenaline | β₁ + β₂ | ↑ HR/contractility + vasodilation → ↓ SVR | Severe bradycardia/chronotropic support; specialist use | IV infusion; very short acting; COMT/MAO metabolism |
| Dobutamine | Predominantly β₁, some β₂/α₁ | ↑ contractility and CO[inotropy], relatively little change in SVR | Low-output cardiac failure/cardiogenic shock with poor contractility | IV infusion; short half-life (~2 min); rapid metabolism |
| Dopamine | Dose-dependent D₁ → β₁ → α₁ | Dose-dependent; Low dose: Vasodilation in renal/mesenteric/cerebral vessels; Mod dose: ↑ contractility + HR; High dose: Vasoconstriction→ ↑ SVR | Selected shock/bradycardia situations; less commonly first-line vasopressor. Methyldopa is used in pregnancy HTN as it ↓ PVR | IV infusion; very short half-life (~2 min); metabolised by MAO/COMT |
What are the different effects of various beta blockers? How is this important in toxicity?
General overview of the adverse effects of beta blockers:
Cold hands: Beta blockade can lead to a rise in peripheral vascular resistance as β₂ vasodilation is blocked, leading to unopposed alpha action. Can worsen claudication in PVD.
Worsening of asthma: β₂ blockade → bronchoconstriction
Sinus bradycardia: beta blockers are contraindicated in patients with symptomatic bradycardia or sinus node dysfunction (↓ AV conduction)
Verapamil interaction: co-administration can lead to bradycardia, heart failure, severe hypotension
Hypoglycaemia: endogenous adrenaline is critical in the counter-regulatory response to hypoglycaemia, so beta blockers should be avoid in insulin-dependent diabetes with frequent hypoglycaemia. β₁-selective antagonist preferred in these patients.
Fatigue, depression
Sexual dysfunction: impaired ejaculation due to GU/GI sphincter activity.
Metabolism and lipids: beta blockade leads to a small increase in triglycerides and decrease in HDL
Acute withdrawal: sudden tachycardia can result from abruptly ceasing beta blockers. Should taper.
| β-blocker type | Examples | Important pharmacology | Toxicity implications |
|---|---|---|---|
| β₁-selective | Metoprolol, atenolol, bisoprolol, esmolol, nebivolol | Preferentially block β₁ at therapeutic doses | Mainly bradycardia, AV block, hypotension. At high doses, selectivity is lost → β₂ effects can occur |
| Non-selective β₁ + β₂ | Propranolol, sotalol, nadolol, timolol | Block both β₁ and β₂ | Cardiovascular toxicity plus bronchospasm, hypoglycaemia/impaired glucose recovery. Some have additional important properties |
| β-blocker + α₁ blockade | Labetalol, carvedilol | β₁ + β₂ + α₁ blockade | More vasodilation → hypotension can be prominent |
| β-blocker with membrane-stabilising activity (MSA) | Propranolol (important), high-dose some others | Blocks fast Na⁺ channels at high concentrations | QRS widening, ventricular dysrhythmias, seizures; particularly important in propranolol overdose |
| β-blocker with K⁺-channel blockade | Sotalol | β-blockade + class III antiarrhythmic effect | QT prolongation → torsades de pointes |
| Short-acting β₁-selective | Esmolol | Very short half-life; rapidly metabolised by esterases | Toxicity generally shorter-lived once stopped |
Special cases to remember
Propranolol is highly lipid soluble and crosses the blood-brain barrier. In overdose you see:
- Beta blockade: bradycardia and hypotension
- CNS toxicity: seizures, coma
- Na+ channel blockage: QRS widening
Sotalol has beta blocking AND class III anti-arrthymic effects. In overdose you see:
- Beta blockage
- K+ channel blockage: QT prolongation, torsades
Beta blockers; their pharmacodynamics and pharmacokinetics
Most beta blockers are well absorbed orally and peak concentrations are 1-3hrs after ingestion. Most have half lives in the range of 3-10 hours (except esmolol).
| Drug | Receptor action | Pharmacodynamics | Pharmacokinetics | Clinical points |
|---|---|---|---|---|
| Propranolol | Non-selective β₁ + β₂ antagonist | ↓ HR, ↓ contractility, ↓ AV conduction, ↓ renin; β₂ blockade → bronchoconstriction | Oral, IV; lipid soluble; extensive first pass hepatic metabolism, low bioavailability, t½ ~3–6 h | CNS effects + Na⁺ channel blockade in overdose Used in thyroid storm, infantile hemangiomas |
| Metoprolol | β₁-selective antagonist | ↓ HR, ↓ contractility, ↓ AV conduction, ↓ renin | Oral, IV; extensive hepatic metabolism (CYP2D6); t½ ~3–7 h | Cardio-selective, but selectivity lost at high doses. Better for asthma/copd |
| Atenolol | β₁-selective antagonist | ↓ HR, ↓ contractility, ↓ AV conduction, ↓ renin | Oral, IV; hydrophilic(doesn’t cross BBB); predominantly renal excretion; t½ ~6–7 h | Less CNS penetration; accumulation in renal impairment |
| Labetalol | β₁ + β₂ + α₁ antagonist | β blockade + α₁ vasodilation → ↓ HR/contractility + ↓ SVR | Oral, IV; hepatic metabolism; t½ ~5–8 h | Produces vasodilation without marked reflex tachycardia, used in pregnancy-associated HTN and hypertensive emergency |
| Esmolol | β₁-selective antagonist | Rapid ↓ HR, contractility and AV conduction | IV only; rapidly hydrolysed by RBC esterases; t½ ~9 min | Ultra-short acting; easily titrated |
| Nebivolol | The most β₁-selective antagonist | ↓ HR, ↓ contractility, ↓ AV conduction, ↓ renin +Vasodilation (Promotes endothelial NO production) | Oral; extensive hepatic metabolism, including CYP2D6; relatively long effective duration; t½ ~10–30 h depending on metabolism | β₁ blockade + NO-mediated vasodilation |
| Timolol | β₁ = β₂ antagonist | Reduces aqueous humour production>reduces intraocular pressure | Topical; t½ ~4-5 h; lacks membrane stabilising properties | Treats glaucoma, topical timolol can cause adverse effects in heart and airways i.e. heart block if co-administered with verapamil |
Alpha blockers; their pharmacodynamics and pharmacokinetics
Alpha blockers can cause (negative effects);
- Orthostatic hypotension (and tachycardia) because they block sympathetic-mediated vasoconstriction. When BP depends on increased sympathetic activity i.e. when standing up, this effect is most pronounced..
- Nasal congestion
- Inhibition of ejaculation(since alpha agonism normally contracts vas deferens/seminal vesicles/bladder neck)
| Drug | Receptor action | Pharmacodynamics | Pharmacokinetics | Clinical points |
|---|---|---|---|---|
| Phentolamine | Reversible α₁ + α₂ antagonist | Vasodilation → ↓ SVR/BP; reflex tachycardia [blocking α₂ removes presynaptic inhibition of noradrenaline] | IV/IM; short acting; hepatic metabolism | Acute α-blockade, e.g. catecholamine excess |
| Phenoxybenzamine | Irreversible α₁ + α₂ antagonist | Persistent vasodilation; ↓ SVR; reflex tachycardia | Oral; covalent/irreversible receptor blockade; effect lasts days | Used to treat Phaeochromocytoma; long acting. Enters CNS so can cause sedation/nausea/fatigue |
| Prazosin | Selective α₁ antagonist, reversible | Vasodilation → ↓ SVR/BP; relaxes bladder/prostate smooth muscle | Oral; hepatic metabolism; t½ ~2–3 h; effect longer than plasma t½ | First-dose of prazosin can cause postural hypotension +/- syncope. Can help w/ urinary retention in BPH. |
| Tamsulosin | Competitive α₁ antagonist | Subtype selection i.e. α₁A + α₁D>α₁B relaxes bladder/prostate smooth muscle | Oral; t½ ~9-15h; hepatic metabolism | Inhibits prostate smooth muscle contraction, less effect on standing BP, higher risk of floppy iris syndrome and sometimes stopped before cataract surgery |
Create Your Own Website With Webador